Literature DB >> 15940634

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

Stephan R Targan1, Carol J Landers, Huiying Yang, Michael J Lodes, Yingzi Cong, Konstantinos A Papadakis, Eric Vasiliauskas, Charles O Elson, Robert M Hershberg.   

Abstract

BACKGROUND & AIMS: Antibody responses to certain microbial antigens define heterogeneous groups of Crohn's patients; multiple and high-level responses to these antigens are associated with aggressive clinical phenotypes. The flagellin, CBir1, identified by investigations in the C3H/HeJBir mouse model, has been identified as a dominant antigen capable of inducing colitis in mice and eliciting antibody responses in a subpopulation of patients with Crohn's disease (CD). The aim of this study was to evaluate serum response to CBir1 flagellin in CD patients and to compare this response to responses defined previously to oligomannan (anti-Saccharomyces cerevisiae antibody), I2, OmpC, and neutrophil nuclear autoantigens (pANCA), and to determine anti-CBir1-associated phenotypes.
METHODS: A total of 484 sera from the Cedars Sinai Medical Center repository, previously typed for anti-Saccharomyces cerevisiae antibody, anti-I2, anti-OmpC, and pANCA were tested for anti-CBir1 by enzyme-linked immunosorbent assay, and results were assessed for clinical phenotype associations.
RESULTS: The presence and level of immunoglobulin G anti-CBir1 were associated with CD independently. Anti-CBir1 was present in all antibody subgroups and expression increased in parallel with increases in the number of antibody responses. pANCA+ CD patients were more reactive to CBir1 than were pANCA+ ulcerative colitis patients. Anti-CBir1 expression is associated independently with small-bowel, internal-penetrating, and fibrostenosing disease features.
CONCLUSIONS: Serum responses to CBir1 independently identify a unique subset of patients with complicated CD. This bacterial antigen was identified in a murine model and has a similar pattern of aberrant reactivity in a subset of CD patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940634     DOI: 10.1053/j.gastro.2005.03.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  145 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 2.  Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.

Authors:  Amit Kaul; Susan Hutfless; Ling Liu; Theodore M Bayless; Michael R Marohn; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

Review 3.  Bone, inflammation, and inflammatory bowel disease.

Authors:  Manasi Agrawal; Shitij Arora; Jianjun Li; Rabin Rahmani; Li Sun; Adam F Steinlauf; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

4.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

5.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 6.  Assessment of stricturing Crohn's disease: Current clinical practice and future avenues.

Authors:  Dominik Bettenworth; Tobias M Nowacki; Friederike Cordes; Boris Buerke; Frank Lenze
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 7.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 8.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Authors:  Brindusa Truta; Dan X Li; Uma Mahadevan; Elena R Fisher; Yunn-Y Chen; Kim Grace; Fernando Velayos; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2013-10-04       Impact factor: 3.199

Review 10.  Novel biomarkers of fibrosis in Crohn's disease.

Authors:  Gianluca Pellino; Pierlorenzo Pallante; Francesco Selvaggi
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.